Michael Hall, MD
Cardiovascular Disease · Jackson, MSNPI 1235340225
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $52,131 of the $54,494 with a category attached, or 95.7%. Cvrx, Inc. accounts for 70.3% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $14,048 and has fallen 87.8% since, to $1,715 in 2025. Among cardiovascular disease clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 47 payments — averaging $1159.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cvrx, Inc.$38K
- Novo Nordisk$14K
- Artivion, Inc.$2K
- Boston Scientific$182
- Atricure, Inc.$150
- Medtronic$38
- plus $83 from 5 others
Across 20 payments — averaging $3671.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ortho-clinical Diagnostics, Inc.$50K
- Artivion, Inc.$16K
- Cvrx, Inc.$4K
- Currax Pharmaceuticals LLC$3K
- Octapharma USA, Inc.$800
What the payments were for
- Consulting fees$52,13196%
- Travel & lodging$1,1792%
- Food & beverage$1,1762%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cvrx, Inc. | 17 | $38,325 |
| Novo Nordisk | 14 | $14,117 |
| Artivion, Inc. | 3 | $1,600 |
| Boston Scientific | 4 | $182 |
| Atricure, Inc. | 1 | $150 |
| Medtronic(2 entities) | 3 | $38 |
| Abbott | 1 | $21 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| Johnson & Johnson | 1 | $14 |
| GE HealthCare | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$38,325
- AMDS-Ascyrus Medical$1,600
- SYNERGY ABLATION SYSTEM$150
How this compares
$54,494 in reported general payments places this provider in the 95th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 72 | $70,203 |
| FarxigaDapagliflozin Propanediol | 58 | $49,960 |
| JardianceEmpagliflozin | 44 | $41,528 |
| XareltoRivaroxaban | 28 | $27,070 |
| EliquisApixaban | 26 | $21,101 |
| Metoprolol Succinate | 97 | $1,256 |
| Atorvastatin Calcium | 117 | $995 |
| Rosuvastatin Calcium | 42 | $625 |
| ClopidogrelClopidogrel Bisulfate | 39 | $601 |
| Midodrine Hcl | 17 | $526 |
| Amlodipine Besylate | 80 | $420 |
| Losartan Potassium | 23 | $412 |
| Hydrochlorothiazide | 63 | $323 |
| Carvedilol | 58 | $297 |
| Nitroglycerin | 12 | $252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $17 | $70,20372 claims |
| Johnson & JohnsonXarelto | $14 | $27,07028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Jackson
- Donny StokesJackson$207K
- James BenslerJackson$64K
- Tahsin QarqishJackson$39K
- Christopher LatourJackson$33K
- Varun SardarJackson$31K
- Olurotimi BaderoJackson$20K
- Michael PaymentJackson$16K
- James HaysJackson$16K
- Douglas HarkinsJackson$14K
- Aditya SabharwalJackson$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.